Ten Years of the Immune Tolerance Network: An Integrated Clinical Research Organization

Immune Tolerance Network, University of California, San Francisco, San Francisco, CA 94107, USA.
Science translational medicine (Impact Factor: 15.84). 02/2010; 2(19):19cm7. DOI: 10.1126/scitranslmed.3000672
Source: PubMed


The U.S. National Institutes of Health Roadmap and the U.S. Food and Drug Administration's Critical Path Initiative have endorsed the establishment of large academic clinical research networks as part of the solution to the growing divide between increased R&D spending and the lagging number of new drugs making it to market. Clearly, the role of these networks as translational science incubators that complement industry-sponsored programs is laudable and much-needed. However, the path to success for such organizations is less clear. Here, drawing on the experiences of the Immune Tolerance Network, a multidisciplinary clinical research network founded in 1999, we discuss some of the barriers inherent in developing such consortia and offer firsthand insight into the planning, resources, and organizational infrastructure required for a successful research program.

Download full-text


Available from: Alan M Krensky, Oct 01, 2015
12 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although studies of the laboratory mouse model have laid the groundwork for our rich understanding of immunobiology, they have fallen short in deciphering human disease and providing much needed therapeutic modalities. Indeed, bench-to-bedside approaches have not been a particularly effective means of developing translational research.(1) Recently, a symposium was held at the National Institutes of Health (NIH) entitled "Meeting the Human Immunology Challenge," highlighting the opportunities for the new Intramural NIH Center for Human Immunology, Autoimmunity, and Inflammation (; among other things it has become clear that a broader definition of the human immune spectrum in health and disease is needed. The human immunology meeting was held in the Clinical Center of the National Institutes of Health, Bethesda, Maryland, on September 3 and 4, 2009.
    Annals of the New York Academy of Sciences 07/2010; 1200 Suppl 1(s1):E1-23. DOI:10.1111/j.1749-6632.2010.05682.x · 4.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Translational research organizations (TROs) seek to enhance the clinical impact of scientific discoveries and play a multifaceted role characterized by multidisciplinary collaboration, outreach initiatives, and the provision of shared resources and facilities. Given this complexity, TROs require a flexible framework for performance assessment that tracks their progress, incentivizes fruitful activities, and aligns individuals throughout the organization. We suggest a framework that assesses TRO performance along seven main dimensions-funding, talent, creation, validation, dissemination, external uptake, and collaboration-and we encourage individual organizations to develop additional metrics as needed.
    Science translational medicine 08/2011; 3(94):94cm20. DOI:10.1126/scitranslmed.3002085 · 15.84 Impact Factor